Статті в журналах: "Myoglobin Assay"

1

Massoubre, Catherine, Laurent Chivot, Francine Mainard, Boumediene Bridji, and Yves Madec. "Immunonephelometric assay of myoglobin." Clinica Chimica Acta 201, no. 3 (September 1991): 223–29. http://dx.doi.org/10.1016/0009-8981(91)90373-k.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Delanghe, J. R., J. P. Chapelle, and S. C. Vanderschueren. "Quantitative nephelometric assay for determining myoglobin evaluated." Clinical Chemistry 36, no. 9 (September 1, 1990): 1675–78. http://dx.doi.org/10.1093/clinchem/36.9.1675.

Повний текст джерела

Анотація:

Abstract A recently introduced automated nephelometric immunoassay involving shell/core particles for determination of myoglobin (Behringwerke) was evaluated with the BNA Nephelometer. Method precision was good: the intra-assay CV varied between 1.5% and 6.1%; with daily calibration, the interassay CV ranged between 1.5% and 7.5%. For usual sample dilutions, the assay response varied linearly with myoglobin concentrations up to 23.1 nmol/L. After automatic dilution by the instrument, concentrations up to 2310 nmol/L could be measured without high-dose "hook" effect. Further manual dilution allowed measurement of myoglobin concentrations up to 26,000 nmol/L. Calibration was stable for at least seven days. We detected no significant interferences from hemoglobin, haptoglobin, bilirubin, iodine-containing contrast media, and rheumatoid factors. Treating lipemic samples with Lipoclean (Behringwerke) decreased test results. Simultaneously drawn serum and plasma samples from the same subject showed no consistent differences in myoglobin concentrations. The mean reference myoglobin concentration was 1.380 (SD 0.82) nmol/L for men and 0.878 (SD 0.45) nmol/L for women. In patients with renal insufficiency, serum creatinine values were moderately related to serum myoglobin values (r = 0.465). Although a commercial radioimmunoassay (Byk-Sangtec) and the nephelometric assay intercorrelated well (r = 0.929), values obtained by nephelometry were significantly lower (P less than 0.05). By both assays, results for heart and skeletal muscle tissue extracts showed no correlation, a finding that suggests the existence of multiple forms of myoglobin in human tissues. We conclude that immunonephelometry is a rapid, practical, and reliable method for measuring myoglobin in serum.

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Gülcü, Özgehan Cansu, and Elvan Üstün. "A simple theoretical approach to converging of Myoglobin-Assay with different pH values." Acta Chimica Slovaca 14, no. 1 (January 1, 2021): 97–104. http://dx.doi.org/10.2478/acs-2021-0012.

Повний текст джерела

Анотація:

Abstract Many metal carbonyl complexes have been synthesized and analyzed as CO-releasing agents. As in many bioactivity assays, differences between in-vitro and in-vivo studies in Myoglobin Assay have been observed. Adjustment of in-vitro conditions to in-vivo conditions is one way to overcoming this problem. Changing the conditions of each in-vivo assay is not possible considering the available grant, material, and labor facilities. In-silico methods are suitable as they provide better in-vitro conditions before experimental procedures. A method which is easy to employ on a basic computer could be more suitable to observe the assay convergence. In this study, global reactivity descriptors were used as an approach to investigate pH differences in myoglobin assay. Global reactivity descriptors of the molecules were compared with myoglobin assay results at different pH values and molecular docking results performed with optimized molecules in different solvents. The following complexes were studied: [Mn(CO)3(bpy)(L)]PF6 (bpy: 2,2-bipyridyl, L: benzylbenzimidazole, 4-chlorobenzylbenzimidazole).

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Vuletich, Jennifer L., and Yoichi Osawa. "Chemiluminescence Assay for Oxidatively Modified Myoglobin." Analytical Biochemistry 265, no. 2 (December 1998): 375–80. http://dx.doi.org/10.1006/abio.1998.2926.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Delanghe, J., J. P. Chapelle, M. El Allaf, and M. De Buyzere. "Quantitative Turbidimetric Assay for Determining Myoglobin Evaluated." Annals of Clinical Biochemistry: An international journal of biochemistry and laboratory medicine 28, no. 5 (September 1, 1991): 474–79. http://dx.doi.org/10.1177/000456329102800509.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Pagani, Franca, Roberto Bonora, Graziella Bonetti, and Mauro Panteghini. "Evaluation of a sandwich enzyme-linked immunosorbent assay for the measurement of serum heart fatty acid-binding protein." Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 39, no. 4 (July 1, 2002): 404–5. http://dx.doi.org/10.1258/000456302760042173.

Повний текст джерела

Анотація:

Background: We evaluated the sandwich enzyme-linked immunosorbent assay (ELISA) MARKIT®-M for the determination of heart fatty-acid-binding protein (H-FABP). Results and Conclusions: The between-run coefficient of variation of this assay was <3·9 and it showed good correlation with a previously established ELISA method. The upper reference limit in 30 healthy individuals was 6·1 μg/L. Admission serum H-FABP was evaluated against myoglobin in 41 patients with suspected myocardial infarction (onset of symptoms ≤ 5 h). H-FABP showed the same diagnostic efficiency as myoglobin [area (standard error) under the receiver operating characteristic curve: 0·798 (0·079) for H-FABP, 0·771 (0·085) for myoglobin, P = 0·55]. However, using the upper reference limit as decision cut-off, the sensitivity for H-FABP [91%; 95% confidence interval (CI): 76-98%] was significantly ( P = 0·019) higher than that of myoglobin (65%; 95% CI: 47-80%).

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Liebetrau, Christoph, Helge Möllmann, Holger Nef, Sebastian Szardien, Johannes Rixe, Christian Troidl, Matthias Willmer, et al. "Release Kinetics of Cardiac Biomarkers in Patients Undergoing Transcoronary Ablation of Septal Hypertrophy." Clinical Chemistry 58, no. 6 (June 1, 2012): 1049–54. http://dx.doi.org/10.1373/clinchem.2011.178129.

Повний текст джерела

Анотація:

Abstract BACKGROUND The release kinetics of cardiac troponin T measured with conventional vs high-sensitivity cardiac troponin T (hs-cTnT) assays in patients with acute myocardial infarction (AMI) is difficult to establish. METHODS We analyzed the release kinetics of cTnT measured by fourth generation and high-sensitivity assays, creatine kinase-MB (CK-MB), and myoglobin in patients with hypertrophic obstructive cardiomyopathy undergoing transcoronary ablation of septal hypertrophy (TASH), a model of AMI. Consecutive patients (n = 21) undergoing TASH were included. Serum and EDTA-plasma samples were collected before and at 15, 30, 45, 60, 75, 90, and 105 min, and 2, 4, 8, and 24 h after TASH. RESULTS cTnT concentrations measured by the hs assay were significantly increased at 15 min [21.4 ng/L, interquartile range (IQR) 13.3–39.7 ng/L vs 11.3 ng/L, IQR 6.0–18.8 ng/L at baseline; P = 0.031]. In comparison, cTnT concentrations measured by the conventional fourth generation assay increased significantly at 60 min (30.0 ng/L, IQR 20.0–30.0 ng/L vs <10.0 ng/L, IQR <10.0–10.0 ng/L; P < 0.01), CK-MB at 90 min (8.4 μg/L, IQR 6.9–14.4 μg/L vs 0.9 μg/L, IQR 0.4–1.1 μg/L; P < 0.01), and myoglobin at 30 min (188.0 μg/L, IQR 154.0–233.0 μg/L vs 38.0 μg/L, IQR 28.0–56.0; P < 0.01). CONCLUSIONS cTnT concentrations measured by the hs assay were significantly increased after TASH at all of the time points, with a doubling at 15 min after induction of AMI, confirming earlier evidence of myocardial injury compared to the fourth generation cTnT assay and CK-MB and myoglobin.

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Zaninotto, Martina, Franca Pagani, Sara Altinier, Paolo Amboni, Roberto Bonora, Alberto Dolci, Patrizia Pergolini, Arialdo Vernocchi, Mario Plebani, and Mauro Panteghini. "Multicenter Evaluation of Five Assays for Myoglobin Determination." Clinical Chemistry 46, no. 10 (October 1, 2000): 1631–37. http://dx.doi.org/10.1093/clinchem/46.10.1631.

Повний текст джерела

Анотація:

Abstract Background: Lacking assay standardization, different myoglobin methods may produce results that differ significantly. Methods: A multicenter study was carried out to compare the analytical performance of five commercially available assays for myoglobin measurement. Linearity, imprecision, interferences, and method comparison were studied according to NCCLS guidelines, whereas reference values were determined following IFCC recommendations. Results: The BNA and Opus showed relatively high imprecision (all but one total CV >7.4%). Other assays showed lower CVs, but they varied among laboratories, particularly at a normal myoglobin concentration (Access, 6.0–11%; Hitachi, 3.8–5.8%; Stratus, 3.4–6.5%). Results were lower in anticoagulated samples on the Access, in heparin and citrate samples on the Stratus, and in citrate samples on the BNA and Opus, and increased in heparin and EDTA samples on the Hitachi. Use of separator gel produced results significantly lower (P <0.001) on the Hitachi and higher (P = 0.016) on the Opus. Bilirubin, turbidity, and hemoglobin had no effect on evaluated methods, but rheumatoid factor affected the Access. In method comparisons, high correlation coefficients (≥0.98) were obtained. The Stratus gave higher results; however, the Access and BNA gave the lowest. The following upper reference limits (μg/L) for men and women, respectively, were obtained: Access, 70 and 52; BNA, 51 and 49; Hitachi, 67 and 58; Opus, 80 and 50; and Stratus, 86 and 63. Conclusion: The possibility of high imprecision and marked disagreement among commercial myoglobin assays should be carefully considered in clinical practice.

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Kumar, Udit, Shilpa Jose, Dhanaraj Divya, Pitchavel Vidhyapriya, Natarajan Sakthivel, and Bala Manimaran. "Self-assembly of manganese(i) based thiolato bridged dinuclear metallacycles: synthesis, characterization, cytotoxicity evaluation and CO-releasing studies." New Journal of Chemistry 43, no. 19 (2019): 7520–31. http://dx.doi.org/10.1039/c8nj06271d.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Marques, Sara S., Luís M. Magalhães, Ana I. P. Mota, Tânia R. P. Soares, Barbara Korsak, Salette Reis, and Marcela A. Segundo. "Myoglobin microplate assay to evaluate prevention of protein peroxidation." Journal of Pharmaceutical and Biomedical Analysis 114 (October 2015): 305–11. http://dx.doi.org/10.1016/j.jpba.2015.06.006.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Bakker, A. J., D. A. Boymans, D. Dijkstra, J. P. Gorgels, and R. Lerk. "Rapid determination of serum myoglobin with a routine chemistry analyzer." Clinical Chemistry 39, no. 4 (April 1, 1993): 653–58. http://dx.doi.org/10.1093/clinchem/39.4.653.

Повний текст джерела

Анотація:

Abstract A turbidimetric immunoassay system (Turbitime system, Behringwerke AG) allows rapid determination of myoglobin in serum. We adapted the reagents for this myoglobin assay (Turbiquant myoglobin) for use with a Hitachi 717 analyzer. No high-dose hook effect was observed up to 15,000 micrograms/L. Interassay CVs were 4.6% (mean = 72.0 micrograms/L; n = 9) and 2.5% (mean = 365.6 micrograms/L; n = 11). The calibration curve was stable for at least 1 month. Hemolysis did not interfere, and turbidity from lipemia interfered only when absorbance exceeded 2.0 A. Results of this method (y) correlated well with those by the Turbitime method (y = 1.256x - 44.1 micrograms/L; n = 91; r = 0.991) and by a commercially available radioimmunoassay (Byk-Sangtec; y = 0.739x - 42.2 micrograms/L; n = 94; r = 0.991). The upper limit (95th percentile) of the reference interval for myoglobin was estimated at 57.9 micrograms/L. The positive predictive value for results of myoglobin at admission was 89% with this upper reference limit and 99% with 100 micrograms/L, whereas the negative predictive value was about 60% for both limits.

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Godber, Benjamin, Kevin SJ Thompson, Marian Rehak, Yildiz Uludag, Sven Kelling, Alexander Sleptsov, Mark Frogley, Klaus Wiehler, Christopher Whalen, and Matthew A. Cooper. "Direct Quantification of Analyte Concentration by Resonant Acoustic Profiling." Clinical Chemistry 51, no. 10 (October 1, 2005): 1962–72. http://dx.doi.org/10.1373/clinchem.2005.053249.

Повний текст джерела

Анотація:

Abstract Background: Acoustic sensors that exploit resonating quartz crystals directly detect the binding of an analyte to a receptor. Applications include detection of bacteria, viruses, and oligonucleotides and measurement of myoglobin, interleukin 1β (IL-1β), and enzyme cofactors. Methods: Resonant Acoustic Profiling™ was combined with a microfluidic lateral flow device incorporating an internal reference control, stable linker chemistry, and immobilized receptors on a disposable sensor “chip”. Analyte concentrations were determined by analyzing the rate of binding of the analyte to an appropriate receptor. Results: The specificity and affinity of antibody–antigen and enzyme–cofactor interactions were determined without labeling of the receptor or the analyte. We measured protein concentrations (recombinant human IL-1β and recombinant human myoglobin) and quantified binding of cofactors (NADP+ and NAD+) to the enzyme glucose dehydrogenase. Lower limits of detection were ∼1 nmol/L (17 ng/mL) for both IL-1β and human myoglobin. The equilibrium binding constant for NADP+ binding to glucose dehydrogenase was 2.8 mmol/L. Conclusions: Resonant Acoustic Profiling detects analytes in a relatively simple receptor-binding assay in <10 min. Potential applications include real-time immunoassays and biomarker detection. Combination of this technology platform with existing technologies for concentration and presentation of analytes may lead to simple, label-free, high-sensitivity methodologies for reagent and assay validation in clinical chemistry and, ultimately, for real-time in vitro diagnostics.

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Innes, Grant, James Christenson, W. Douglas Weaver, Tiepu Liu, James Hoekstra, Nathan Every, Raymond E. Jackson, Paul Frederick, and W. Brian Gibler. "Diagnostic parameters of CK–MB and myoglobin related to chest pain duration." CJEM 4, no. 05 (September 2002): 322–30. http://dx.doi.org/10.1017/s1481803500007715.

Повний текст джерела

Анотація:

ABSTRACT:Objective:Cardiac marker sensitivity depends on chest pain duration at the time of sampling. Our objective was to estimate the sensitivity, specificity, and likelihood ratios of early CK–MB and myoglobin assays in patients presenting to the emergency department (ED) with nondiagnostic ECGs, stratified by the duration of ongoing chest pain at the time of ED assessment.Methods:This was a prospective observational study carried out in 10 US and 2 Canadian EDs. Patients >25 years of age with ongoing chest pain and nondiagnostic ECGs were stratified by pain duration (0–4 h, 4–8 h, 8–12 h, >12 h). CK–MB and myoglobin assays were drawn at T = 0 (ED assessment) and T = 1 hr. Patients were followed for 7–14 days to identify all cases of acute myocardial infarction (AMI). ED test results were correlated with patient outcomes.Results:Of 5005 eligible patients, 565 had AMI. Pain duration was 0–4 h in 3014 patients, 4–8 h in 961, 8–12 h in 487, and >12 h in 543. Marker sensitivity increased with pain duration, ranging from 28%–77% for CK–MB and 39%–73% for myoglobin. The maximal sensitivity achieved by a T = 0 assay was 73%, and this was in patients with 8–12 or >12 h of ongoing pain. No combination of tests achieved 90% sensitivity in any pain duration strata.Conclusions:Regardless of chest pain duration, single assays and early serial markers (0+1 hr) do not rule out AMI; therefore, serial assays over longer observation periods are required. Likelihood ratios derived in this study will help physicians who use Bayesian analysis to determine post-test AMI likelihood in patients with chest pain.

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Van Blerk, M., V. Maes, L. Huyghens, M. P. Derde, R. Meert, and F. K. Gorus. "Analytical and Clinical Evaluation of Creatine Kinase MB Mass Assay by IMx: Comparison with MB Isoenzyme Activity and Serum Myoglobin for Early Diagnosis of Myocardial Infarction." Clinical Chemistry 38, no. 12 (December 1, 1992): 2380–86. http://dx.doi.org/10.1093/clinchem/38.12.2380.

Повний текст джерела

Анотація:

Abstract We analytically and clinically evaluated Abbott's IMx assay for creatine kinase (CK) isoenzyme MB (CK-MB) in serum. Over a 1-year period, the method was more specific but less precise than catalytic isoenzyme measurements by electrophoresis or immunoinhibition. Sera from different individuals without electrophoretic evidence of CK-MB but containing macro CK type 1 (n = 20), mitochondrial CK (n = 5), or CK-BB (n = 5) were scored as CK-MB negative by the IMx. Likewise, CK-MB-negative by the sera remained so after addition of purified human CK-MM (< or = 7600 U/L) or CK-BB (< or = 8100 U/L). For 39 patients admitted for suspicion of uncomplicated acute myocardial infarction (precordial pain for < or = 4 h), the diagnostic performance of the IMx CK-MB assay on admission and 4 h later was superior to that of total CK activity and compared well with that of CK-MB activity measured by electrophoresis or immunoinhibition. An admission, myoglobin showed a higher diagnostic sensitivity, specificity, and predictive value than did CK-MB and was the most informative test. Diagnostic performance on admission and 4 h later was further improved by considering positivity for myoglobin and for CK-MB by IMx and for the change in each over the first 4 h of hospitalization as criteria. Twelve hours after admission, diagnostic performance was further improved for all CK and CK-MB methods but began to decline for myoglobin.

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Vrenna, L., A. M. Castaldo, P. Castaldo, D. Giardiello, C. Di Giacomo, L. P. Esposito, and F. Romano. "Comparison between Nephelometric and RIA Methods for Serum Myoglobin, and Efficiency of Myoglobin Assay for Early Diagnosis of Myocardial Infarction." Clinical Chemistry 38, no. 5 (May 1, 1992): 789–90. http://dx.doi.org/10.1093/clinchem/38.5.789.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

&NA;. "A rapid and effective myoglobin assay for the detection of myocardial infarction." Inpharma Weekly &NA;, no. 792 (June 1991): 1. http://dx.doi.org/10.2165/00128413-199107920-00003.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Yue, Qiaoli, and Zhenghua Song. "Assay of femtogram level nitrite in human urine using luminol–myoglobin chemiluminescence." Microchemical Journal 84, no. 1-2 (September 2006): 10–13. http://dx.doi.org/10.1016/j.microc.2006.03.005.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Atkin, Anthony J., Jason M. Lynam, Benjamin E. Moulton, Philip Sawle, Roberto Motterlini, Nicola M. Boyle, Mary T. Pryce, and Ian J. S. Fairlamb. "Modification of the deoxy-myoglobin/carbonmonoxy-myoglobin UV-vis assay for reliable determination of CO-release rates from organometallic carbonyl complexes." Dalton Transactions 40, no. 21 (2011): 5755. http://dx.doi.org/10.1039/c0dt01809k.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Mikkelsen, Anni, Laurette Sosniecki, and Leif H. Skibsted. "Myoglobin catalysis in lipid oxidation Assay for activity with linoleic acid as substrate." Zeitschrift f�r Lebensmittel-Untersuchung und -Forschung 195, no. 3 (September 1992): 228–34. http://dx.doi.org/10.1007/bf01202800.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Collinson, Paul O., Nigel Wiggins, and David C. Gaze. "Clinical Evaluation of the ACS:180 Cardiac Troponin I Assay." Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 38, no. 5 (September 2001): 509–19. http://dx.doi.org/10.1177/000456320103800508.

Повний текст джерела

Анотація:

All patients admitted to the coronary care unit with suspected acute coronary syndromes were evaluated by serial electrocardiography and blood draws on admission and at 4 and 12h from admission. Diagnosis was based on conventional WHO criteria. Samples were measured for creatine kinase (CK), cardiac troponin T (cTnT), myoglobin, CK isoenzyme MB (CK-MB) and cardiac troponin I (cTnI). A set of samples from individuals undergoing extreme endurance training was also examined. Analytical imprecision was consistent with published quality goals. Samples were stable for cTnI under a range of storage conditions, including multiple freeze-thaw cycles. CK-MB, cTnI and cTnT were equally efficient for the diagnosis of acute myocardial infarction, irrespective of the final diagnostic criteria used. Both cTnI and cTnT were of equal efficiency in the identification of a high-risk subgroup of patients with unstable angina. Significant elevations of cTnI were not seen in an endurance-training group.

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Jeyasingham, M. D., O. E. Pratt, and H. K. Roopral. "Interaction between pyridine nucleotide coenzymes and heme proteins as a possible source of error in assay of activities of coenzyme-linked enzyme." Clinical Chemistry 35, no. 10 (October 1, 1989): 2129–33. http://dx.doi.org/10.1093/clinchem/35.10.2129.

Повний текст джерела

Анотація:

Abstract The ultraviolet absorbance spectra of pyridine nucleotide coenzymes change in the presence of heme-containing proteins. The positions of each of the two main absorbance peaks of NADH are shifted progressively towards shorter wavelengths in the presence of increasing concentrations of hemoglobin, and the third peak, at 220 nm, disappears altogether. Similar changes are seen in the spectra of NAD+ and NADPH, and similar effects on these spectra are produced by myoglobin and cytochrome c, but not by comparable concentrations of albumin. The spectral shifts are generally accompanied by a decreased peak height. This finding may help explain problems reported by previous workers in the measurement of the activity of enzymes such as transketolase or lactate dehydrogenase in erythrocyte hemolysates. Errors may be considerable if allowance is not made for this effect, especially if the concentration of heme protein in the spectrophotometer cuvette much exceeds 1 g/L. The interaction appears to indicate some form of bonding, occurring generally between pyridine nucleotide coenzymes and the heme group in proteins. We relate the findings to measurement of activities of pyridine nucleotide-linked enzymes in erythrocyte lysates and in plasma containing myoglobin after muscle breakdown.

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Al-Enezi, Eiman, Alexandre Vakurov, Amy Eades, Mingyu Ding, Gin Jose, Sikha Saha, and Paul Millner. "Affimer-Based Europium Chelates Allow Sensitive Optical Biosensing in a Range of Human Disease Biomarkers." Sensors 21, no. 3 (January 27, 2021): 831. http://dx.doi.org/10.3390/s21030831.

Повний текст джерела

Анотація:

The protein biomarker measurement has been well-established using ELISA (enzyme-linked immunosorbent assay), which offers good sensitivity and specificity, but remains slow and expensive. Certain clinical conditions, where rapid measurement or immediate confirmation of a biomarker is paramount for treatment, necessitate more rapid analysis. Biosensors offer the prospect of reagent-less, processing-free measurements at the patient’s bedside. Here, we report a platform for biosensing based on chelated Eu3+ against a range of proteins including biomarkers of cardiac injury (human myoglobin), stroke (glial fibrillary acidic protein (GFAP)), inflammation (C-reactive protein (CRP)) and colorectal cancer (carcinoembryonic antigen (CEA)). The Eu3+ ions are chelated by modified synthetic binding proteins (Affimers), which offer an alternative targeting strategy to existing antibodies. The fluorescence characteristics of the Eu3+ complex with modified Affimers against human myoglobin, GFAP, CRP and CEA were measured in human serum using λex = 395 nm, λem = 590 and 615 nm. The Eu3+-Affimer based complex allowed sensitive detection of human myoglobin, GFAP, CRP and CEA proteins as low as 100 fM in (100-fold) diluted human serum samples. The unique dependence on Eu3+ fluorescence in the visible region (590 and 615 nm) was exploited in this study to allow rapid measurement of the analyte concentration, with measurements in 2 to 3 min. These data demonstrate that the Affimer based Eu3+ complexes can function as nanobiosensors with potential analytical and diagnostic applications.

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Vuori, Juhani, Simo Rasi, Timo Takala, and Kalervo Väänänen. "Dual-label time-resolved fluoroimmunoassay for simultaneous detection of myoglobin and carbonic anhydrase III in serum." Clinical Chemistry 37, no. 12 (December 1, 1991): 2087–92. http://dx.doi.org/10.1093/clinchem/37.12.2087.

Повний текст джерела

Анотація:

Abstract We developed a dual-labeled time-resolved fluoroimmunoassay for simultaneous quantification of myoglobin (Mb) and carbonic anhydrase III (CA III) in serum involving polyclonal antibodies and the fluorescent lanthanides europium (Eu3+) and samarium (Sm3+). This solid-phase immunoassay is based on competition between Eu3+- or Sm(3+)-labeled antigen and the sample antigen for polyclonal rabbit antibodies. Standards and patients' samples containing antigen inhibit binding of the lanthanide-labeled antigen to the antibody. A second antibody directed against rabbit IgG is coated on a solid phase and binds the IgG-antigen-lanthanide complex, giving rapid and complete separation of antibody-bound and free antigen. The assay requires only one incubation step. An enhancement solution dissociates Eu3+ and Sm3+ ions from the labeled CA III and Mb, respectively, into a solution where they form highly fluorescent chelates. Spectra of the fluorescent chelates in the microtitration-strip wells were run on a time-resolved fluorometer equipped with filters for Eu3+ (613 nm) and Sm3+ (643 nm), the fluorescence from each sample being inversely proportional to the concentration of antigens. The measurement range for both analytes is from 5 to 1500 μg/L. The mean within-and between-assay precisions (CV) were 4.6% and 6.2% for CA III and 5.9% and 7.3% for Mb, respectively. Good correlations were obtained with the results of CA III RIA and a commercial myoglobin RIA kit.

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Hänseler, E., P. C. Baumann, Katharina M. Rentsch, and Silvia Brogli. "A new rapid and sensitive immunofluorescence assay for the determination of myoglobin in serum." LaboratoriumsMedizin 17, no. 4 (January 1993): 146–51. http://dx.doi.org/10.1515/labm.1993.17.4.146.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Sypniewska, Grazyna, Marcin Sawicki, Magdalena Krintus, Marek Kozinski, and Jacek Kubica. "The Use of Biochip Cardiac Array Technology for Early Diagnosis of Acute Coronary Syndromes." Journal of Medical Biochemistry 28, no. 4 (October 1, 2009): 293–99. http://dx.doi.org/10.2478/v10011-009-0025-8.

Повний текст джерела

Анотація:

The Use of Biochip Cardiac Array Technology for Early Diagnosis of Acute Coronary SyndromesSerum troponin is the best biomarker for the diagnosis of acute coronary syndrome, but it takes considerable time before a definitive diagnosis is available. The purpose of this study was to evaluate whether a multimarker approach, using the biochip cardiac array, would facilitate the early diagnosis. Serum biomarkers were determined on admission (≤6 hrs) and after 6 hours in 42 patients suspected for ACS. Cardiac troponin I was measured by a sensitive assay (STATcTnI) and cardiac markers (H-FABP, myoglobin, cTnI, CK-MB mass, carbonic anhydrase III) were assayed with the use of Biochip Array Technology.STATcTnI concentrations, within the first 6 hours, were elevated >99thpercentile for the reference population in 83.3% of subjects, but none reached the cut-off for AMI. On admission H-FABP was the only marker with 90.5% sensitivity in all ACS cases and 100% sensitivity in STEMI/NSTEMI patients. The sensitivity of myoglobin at presentation was 71.4% in ACS, however, combined sensitivity of myoglobin and H-FABP reached 95.2%. Lowering the cut-off for cTnI allowed early diagnosis (≤6 hrs) in only 26.2% of ACS patients and 95.2% after the next 6 hours. In unstable angina the cardiac panel was not sufficiently accurate for early risk stratification. In conclusion, testing for both markers, H-FABP and sensitive cardiac troponin, available with the cardiac array may facilitate the early detection of myocardial injury in clinical practice.

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Lane, R. J. M., A. Emslie-Smith, I. E. Mosquera, and P. Hudgson. "Clinical, Biochemical and Histological Responses to Treatment in Polymyositis: A Prospective Study." Journal of the Royal Society of Medicine 82, no. 6 (June 1989): 333–38. http://dx.doi.org/10.1177/014107688908200607.

Повний текст джерела

Анотація:

Routine methods of monitoring treatment responses in polymyositis patients, such as clinical strength assessments and measurements of ESR and serum creatine kinase, have been compared with functional strength measurements and assay of serum myoglobin levels, in a prospective study of nine cases followed for up to five years. Seven patients also underwent serial muscle biopsies during the first year of treatment in order to document the nature and chronology of histological changes during therapy. Inflammatory and necrobiotic changes indicating active myositis resolved within six months in all cases and no patient developed histological evidence of steroid myopathy. Scores on functional muscle strength assessments improved more slowly than static manual muscle strength test results, reflecting morphometric and architectural abnormalities in the biopsies which persisted throughout the period of observation. Serum creatine kinase levels returned to normal more rapidly than serum myoglobin. No statistical relationship was found between muscle strength measurements and biochemical or histological changes within the patients as a group, but variations in these indices in individual subjects reflected changes in clinical state.

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Mair, J., E. Artner-Dworzak, P. Lechleitner, B. Morass, J. Smidt, I. Wagner, F. Dienstl, and B. Puschendorf. "Early diagnosis of acute myocardial infarction by a newly developed rapid immunoturbidimetric assay for myoglobin." Heart 68, no. 11 (November 1, 1992): 462–68. http://dx.doi.org/10.1136/hrt.68.11.462.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Le Moigne, Françoise, Marie-Christine Beauvieux, Philippe Derache, and Yves-Michel Darmon. "Determination of myoglobin: comparative evaluation of the new automated VIDASR assay with two other immunoassays." Clinical Biochemistry 35, no. 4 (June 2002): 255–62. http://dx.doi.org/10.1016/s0009-9120(02)00306-5.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Onuoha, Gracey N., E. Kaya Alpar, Michel Laprade, Daniel Rama, and Bernard Pau. "LEVELS OF MYOSIN HEAVY CHAIN FRAGMENTS IN MYOSKELETAL INJURIES." Journal of Musculoskeletal Research 05, no. 02 (June 2001): 89–93. http://dx.doi.org/10.1142/s0218957701000453.

Повний текст джерела

Анотація:

Myosin heavy chain (MHC) is a structurally bound contractile protein of the thick filaments. The magnitude of myoskeletal injury may be estimated by serial determinations of these contractile proteins released into the circulation as a consequence of loss of cell membrane integrity. The polymorphism of MHC is believed to be responsible, at least in part, for the variable contraction velocity of muscles. It was the aim of the present study to confirm the utility of MHC for the assessment of skeletal muscle damage within 24 hr of injury in patients with myoskeletal injuries. Plasma MHC fragments was measured in 25 patients with muscle injuries. Samples were obtained immediately on hospital admission (A1) and 24 hr after admission (A2). These were compared with 15 noninjured controls. In addition, creatine kinase (CK), myoglobin and cardiac troponin I (cTnI) were measured in order to confirm the extent of the injury and to exclude protein released from the heart. Radioimmunoassay, enzyme immunoassay, and one-step immunoenzymometric assay (IEMA) techniques were used for measurements of plasma MHC fragments, CK plus myoglobin and cTnI, respectively. Mean (SD) uU/l of MHC was (94.1±116.1) p=NS and (673.3±1943) p<0.0001 on A1 and A2, respectively, compared to controls (96.8±96.35). CK (IU/l) was 226.0±231.0 on A1 and 451.0±678.0 on A2 compared to 104.0±51.0 on controls. Myoglobin was 200% higher at A1 and A2 than at controls. We substantiate previous study and conclude that MHC could be a useful tool in the study of myoskeletal injuries in human.

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Zaninotto, M., S. Altinier, M. Lachin, P. Carraro, and M. Plebani. "Fluoroenzymometric method to measure cardiac troponin I in sera of patients with myocardial infarction." Clinical Chemistry 42, no. 9 (September 1, 1996): 1460–66. http://dx.doi.org/10.1093/clinchem/42.9.1460.

Повний текст джерела

Анотація:

Abstract The aim of our study was to evaluate the clinical relevance of serum troponin I (TnI) as a marker of ischemic myocardial injury by using an automated fluoroenzymometric assay. The reference range for serum TnI was established by measuring serum TnI concentrations in blood from 75 healthy donors. The concentration was then compared with serum creatine kinase (CK) activity, CK-MB mass, and myoglobin concentrations in 20 patients with myocardial infarction diagnosed according to the WHO criteria, 20 patients with chest pain of nonischemic origin, 9 patients with unstable angina, 11 with stable angina, 11 patients with chronic muscular diseases, 6 patients with muscular trauma without chest contusion, and 13 patients with chronic renal disease. We found that: (a) 99% of the blood donors had TnI concentrations <0.26 microgram/L (detection limit of the assay in our study); (b) TnI values in acute myocardial infarction (AMI) patients 4 h after onset of chest pain showed a sensitivity of 0.769 and a specificity of 1.0 at a decisional concentration for AMI of 1 microgram/L, even in the presence of severe skeletal muscle injuries or renal diseases; (c) the increase in TnI concentrations after infarction (interquartile range 3.25-6 h) and the peak occurred later (interquartile range 11.5-24 h) than the rise found in myoglobin and CK-MB, but the increase persisted much longer (>96 h); (d) receiver-operating characteristic curve analysis showed the high diagnostic accuracy of TnI in diagnosing AMI even in patients in whom traditional biochemical markers are adversely influenced by underlying clinical situations.

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Singh, P., F. Moll, S. H. Lin, C. Ferzli, K. S. Yu, R. K. Koski, R. G. Saul, and P. Cronin. "Starburst dendrimers: enhanced performance and flexibility for immunoassays." Clinical Chemistry 40, no. 9 (September 1, 1994): 1845–49. http://dx.doi.org/10.1093/clinchem/40.9.1845.

Повний текст джерела

Анотація:

Abstract Starburst dendrimers are novel, water-soluble polymeric materials, with a well-defined composition and structure. In our application, we used dendrimers composed of poly(amidoamine) groups to which we coupled several specific antibodies, to investigate potential formats based on radial partition immunoassay. The coupled antibodies have retained their stability and immunological binding after coupling, both in solution and when immobilized onto a solid support. On the basis of our feasibility studies with model systems, we conclude that immunoassays can be developed with performance equivalent to or better than that in many established systems. By application of a mixture of the dendrimer-coupled antibody and the analyte of interest to the solid phase, we have investigated the performance characteristics of solution-phase immunoassays. Our experiments demonstrate enhanced sensitivity for creatine kinase MB isoenzyme (CKMB), thyrotropin, and myoglobin assays and reduced instrumental analysis time for the CKMB assay.

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Ghosh, Ruchira, and Jayashree Arcot. "Comparison of Intestinal Iron Uptake From Different Plant and Animal Proteins and Food Matrices: Studies Using an In Vitro Digestion/Caco-2 Cell Culture Model." Current Developments in Nutrition 6, Supplement_1 (June 2022): 1183. http://dx.doi.org/10.1093/cdn/nzac074.012.

Повний текст джерела

Анотація:

Abstract Objectives The aim of this study was to assess the effect of cyanocobalamin on intestinal iron uptake in the presence of different plant and animal proteins and food matrices. Methods Different proteins and foods with added iron and cyanocobalamin were digested using Infogest digestion protocol with minor changes. Concentrations of added ferrous sulphate (FeSO4) and B12 was 10 μmol/L and 50 μmol/L in the digesta. Digesta was introduced into Caco-2 cells for 12 hours. Growth medium was removed, and cells were washed twice with ice cold Phosphate-buffered saline (PBS). Cells were harvested by adding an aliquot of deionized water, placing them in a sonicator at 4°C for 15 min, then scraped, collected with 2 mL water in each well, stored at −20°C. The harvested cell suspension was used to analyse ferritin and total protein concentrations using ferritin solid-phase sandwich enzyme-linked immunosorbent assay (ELISA) and Pierce Bicinchoninic acid assay (BCA) respectively. The ratio of ferritin/total protein expressed as ng ferritin/mg protein was used as an index of cellular iron uptake. Results Bioavailability of FeSO4 was higher in the presence of animal proteins (22.20 ± 3.35, 19.77 ± 2.90, 41.52 ± 2.74 ng ferritin/mg protein for casein, egg albumin, myoglobin respectively) when compared with plant proteins (16.47 ± 1.63, 15.84 ± 2.40, 13.37 ± 3.68 ng ferritin/mg protein for gluten, rice, pea protein respectively). Vitamin B12 improved the bioavailability of FeSO4 in the Caco-2 cell model. With the final concentration of cyanocobalamin at 50 mmol/L, ferritin-protein ratio for casein, egg albumin, myoglobin, gluten, rice, pea protein increased 1.3, 1.3, 1.2, 1.6, 1.5, 1.6 times respectively. Similarly, for milk, yogurt, Indian flat bread, bread, rice pancake and rice-pea pancake, addition of vitamin B12 improved ferritin-protein ratio 1.5, 1.1, 1.4, 1.2, 1.6, 1.5 times respectively compared to only FeSO4 fortification. Conclusions Cyanocobalamin promotes iron uptake from FeSO4 in presence of different proteins. Whole foods initiate more iron uptake than protein isolates. Among the protein isolates, myoglobin shows highest iron uptake. Yogurt shows highest intestinal iron uptake in the presence of cyanocobalamin and rice-pea mix could be one of the best options for vegan diet in terms of iron bioavailability. Funding Sources There was no external funding.

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Rabitzsch, G., J. Mair, P. Lechleitner, F. Noll, U. Hofmann, E. G. Krause, F. Dienstl, and B. Puschendorf. "Immunoenzymometric assay of human glycogen phosphorylase isoenzyme BB in diagnosis of ischemic myocardial injury." Clinical Chemistry 41, no. 7 (July 1, 1995): 966–78. http://dx.doi.org/10.1093/clinchem/41.7.966.

Повний текст джерела

Анотація:

Abstract With a new immunoenzymometric assay we measured human glycogen phosphorylase isoenzyme BB (GPBB) in 116 healthy individuals, 14 patients with stable angina, 107 nontraumatic chest pain patients on admission to the emergency department [45 acute myocardial infarction (AMI), 49 unstable angina, 13 other diseases], and in serial samples from 41 AMI patients. GPBB was compared with creatine kinase (CK), CKMB mass, myoglobin, and cardiac troponin T. Receiver-operating characteristic plots demonstrated the significantly greater (P < or = 0.012) discriminatory power of GPBB to detect acute ischemic coronary syndromes compared with all other tested markers. GPBB was the most sensitive marker for detection of AMI during the first 4 h after onset of chest pain, and only GPBB was increased above the upper reference limit (7 micrograms/L) on admission in patients who had unstable angina at rest and reversible ST-T alterations. This and the high early sensitivity of GPBB are most likely explained by its function as a key enzyme of glycogenolysis.

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Rubtsova, Maya Yu, and Elizaveta M. Gavrilov. "An Assay for Human Myoglobin Using the Technique of Membrane Immunoassay with Light-Sensitive Nylon Supports." Analytical Letters 27, no. 15 (December 1994): 2961–71. http://dx.doi.org/10.1080/00032719408000304.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Ji, Tianxing, Xinqiang Xu, Xindong Wang, Qiang Zhou, Weidong Ding, Bo Chen, Xuguang Guo, Yanqiang Hao, and Guanying Chen. "Point of care upconversion nanoparticles-based lateral flow assay quantifying myoglobin in clinical human blood samples." Sensors and Actuators B: Chemical 282 (March 2019): 309–16. http://dx.doi.org/10.1016/j.snb.2018.11.074.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Silva, D. P., Y. Landt, S. E. Porter, and J. H. Ladenson. "Development and application of monoclonal antibodies to human cardiac myoglobin in a rapid fluorescence immunoassay." Clinical Chemistry 37, no. 8 (August 1, 1991): 1356–64. http://dx.doi.org/10.1093/clinchem/37.8.1356.

Повний текст джерела

Анотація:

Abstract Myoglobin (Mb) is considered a useful marker for early detection of myocardial infarction and for monitoring cardiac reperfusion after thrombolytic therapy. We developed eight monoclonal antibodies to human cardiac Mb, characterized their epitopic reactivity, and determined which combinations of the antibodies are useful in two-site immunoassays. We configured two of the monoclonal antibodies in a one-step, two-site particle concentration fluorescence immunoassay (PCFIA) for measurement of Mb. The PCFIA has rapid kinetics of reaction, being complete in 15 min, and has a linear analytical range of 20-675 micrograms/L for human Mb. Although the PCFIA has a high-dose "hook" effect, this is of no analytical importance at concentrations of Mb less than or equal to 148,000 micrograms/L. The assay is not subject to interference from icterus (bilirubin less than or equal to 360 mg/L), has no cross-reaction with hemoglobin (less than or equal to 42 g/L), and may be performed with either plasma or serum in approximately 1 h. The intra- and interassay imprecisions (CV) of the method are less than 10% for concentrations of Mb within the normal range and less than 4% at higher concentrations. A comparison of the PCFIA with a commercial radioimmunoassay showed that results of the two assays correlate well (PCFIA = 0.88 x RIA + 18, r = 0.990, n = 171).

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Xie, Xiaofeng, Xili He, and Zhenghua Song. "A Sensitive Chemiluminescence Procedure for the Determination of Carbon Monoxide with Myoglobin—Luminol Chemiluminescence System." Applied Spectroscopy 61, no. 7 (July 2007): 706–10. http://dx.doi.org/10.1366/000370207781393398.

Повний текст джерела

Анотація:

A novel chemiluminescence method combined with the flow injection technique for the determination of carbon monoxide is presented in this paper. The chemiluminescence signal based on the reaction between myoglobin and luminol in an alkaline medium was remarkably enhanced by carbon monoxide. The enhanced chemiluminescence intensity was linear with carbon monoxide concentration in the range from 0.01 to 10.0 pmol·L−1, and the detection limit was 3 × 10−3 pmol·L−1 (3σ). The whole process, including sampling and washing, could be completed in 0.5 min with a relative standard deviation of less than 4.0%. The proposed method was applied successfully in the assay of carbon monoxide in human serum and artificial water samples without any pretreatment procedure.

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Di, Jia-Yin, Zong-Xin Zhang, and Shao-Jun Xin. "Glycogen Phosphorylase Isoenzyme Bb, Myoglobin and BNP in ANT-Induced Cardiotoxicity." Open Life Sciences 13, no. 1 (December 31, 2018): 561–68. http://dx.doi.org/10.1515/biol-2018-0067.

Повний текст джерела

Анотація:

AbstractAnthracyline (ANT) has been demonstrated as a useful treatment for leukemia and solid tumors. However, ANT has previously reported cardiotoxic effects, which can reduce the therapeutic index for cancer treatment. This study aimed to investigate the associations of glycogen phosphorylase isoenzyme BB (GPBB), myoglobin (Mb), and brain natriuretic peptide (BNP) with anthracycline (ANT-induced cardiotoxicity (AIC)) amongst the Chinese population. Patients suffering from leukemia were recruited. Electrocardiogram and echocardiography were used along with chemotherapy to determine left ventricular ejection fraction (LVEF), mitral ratio of peak early to late diastolic filling velocity (E/A), E-wave deceleration time (EDT), and isovolumic relaxation time (IVRT). Double-antibody sandwich enzyme-linked immunosorbent assay (DAS-ELISA) was employed to examine and compare serum GPBB, Mb, and BNP levels. Following chemotherapy, the patients presented higher levels of serum GPBB, Mb, and BNP than before chemotherapy treatment. The levels of LVEF (%), E/A, and IVRT were significantly decreased after chemotherapy, while EDT was markedly increased. The cumulative ANT dose was positively corelated to serum GPBB, Mb, and BNP levels while it was negatively corelated to LVEF levels. In conclusion, serum GPBB, Mb, and BNP levels in combination might provide higher diagnostic accuracy in the early detection of AIC compared with other single indicators.

Стилі APA, Harvard, Vancouver, ISO та ін.

39

De Lemos, J. A., E. A. Antman, and R. P. Giugliano. "Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogram." ACC Current Journal Review 10, no. 1 (January 2001): 15. http://dx.doi.org/10.1016/s1062-1458(00)00162-8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

40

de Lemos, James A., Elliott M. Antman, Robert P. Giugliano, David A. Morrow, Carolyn H. McCabe, Andrew Charlesworth, Rolf Schröder, and Eugene Braunwald. "Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogram." American Heart Journal 140, no. 3 (September 2000): 373–78. http://dx.doi.org/10.1067/mhj.2000.109216.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Edwards, Katie A., Katherine J. Meyers, Barbara Leonard, and Antje J. Baeumner. "Superior performance of liposomes over enzymatic amplification in a high-throughput assay for myoglobin in human serum." Analytical and Bioanalytical Chemistry 405, no. 12 (February 27, 2013): 4017–26. http://dx.doi.org/10.1007/s00216-013-6807-3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Faizan, Muhammad, Kifayat Ullah Khan Niazi, Niaz Muhammad, Yongxia Hu, Yanyan Wang, Dezhi Lin, Yuanyuan Liu, Weiqiang Zhang, and Ziwei Gao. "The Intercalation of CORM-2 with Pharmaceutical Clay Montmorillonite (MMT) Aids for Therapeutic Carbon Monoxide Release." International Journal of Molecular Sciences 20, no. 14 (July 14, 2019): 3453. http://dx.doi.org/10.3390/ijms20143453.

Повний текст джерела

Анотація:

The pharmaceutical clay montmorillonite (MMT) is, for the first time, explored as a carbon monoxide-releasing material (CORMat). MMT consists of silicate double layered structure; its exfoliation feature intercalate the CORM-2 [RuCl(μ-Cl)(CO)3]2 inside the layers to suppress the toxicity of organometallic segment. The infrared spectroscopy (IR) confirmed the existence of ruthenium coordinated carbonyl ligand in MMT layers. The energy-dispersive X-ray spectroscopy (EDX) analysis showed that ruthenium element in this material was about 5%. The scanning electron microscopy (SEM) and transmission electron microscope (TEM) images showed that the layer-structure of MMT has been maintained after loading the ruthenium carbonyl segment. Moreover, the layers have been stretched out, which was confirmed by X-ray diffraction (XRD) analysis. Thermogravimetric (TG) curves with huge weight loss around 100–200 °C were attributed to the CO hot-release of ruthenium carbonyl as well as the loss of the adsorbed solvent molecules and the water molecules between the layers. The CO-liberating properties have been assessed through myoglobin assay. The horse myoglobin test showed that the material could be hydrolyzed to slowly release carbon monoxide in physiological environments. The half-life of CO release was much longer than that of CORM-3, and it has an excellent environmental tolerance and slow release effect.

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Zhu, Jimin, Nengli Zou, Danian Zhu, Jin Wang, Qinghui Jin, Jianlong Zhao, and Hongju Mao. "Simultaneous Detection of High-Sensitivity Cardiac Troponin I and Myoglobin by Modified Sandwich Lateral Flow Immunoassay: Proof of Principle." Clinical Chemistry 57, no. 12 (December 1, 2011): 1732–38. http://dx.doi.org/10.1373/clinchem.2011.171694.

Повний текст джерела

Анотація:

BACKGROUNDAlthough numerous lateral flow immunoassays (LFIAs) have been developed and widely used, inadequate analytical sensitivity and the lack of multiple protein detection applications have limited their clinical utility. We developed a new LFIA device for the simultaneous detection of high-sensitivity cardiac troponin I (hs-cTnI) and myoglobin (Myo).METHODSWe used a gold nanoparticle (AuNP) doubly labeled complex, in which biotinylated single-stranded DNA was used as a linkage to integrate 2 AuNPs and streptavidin-labeled AuNP, as an amplifier to magnify extremely low signals.RESULTSThe detection limit of 1 ng/L achieved for hs-cTnI was 1000 times lower than that obtained in a conventional LFIA. The detection limit for simultaneously measured Myo was 1 μg/L. The linear measurement ranges for hs-cTnI and Myo were 1–10 000 ng/L and 1–10 000 μg/L, respectively. We observed concordant results between the LFIA and clinical assays in sera from 12 patients with acute myocardial infarction (hs-cTnI r = 0.96; Myo r = 0.98). Assay imprecision was <11% for both hs-TnI and myo.CONCLUSIONSThe described proof-of-principle LFIA method could be used as a point-of-care device in multiple protein quantification and semiquantitative analysis.

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Byzova, Nadezhda A., Yuri Yu Vengerov, Sergey G. Voloshchuk, Anatoly V. Zherdev, and Boris B. Dzantiev. "Development of a Lateral Flow Highway: Ultra-Rapid Multitracking Immunosensor for Cardiac Markers." Sensors 19, no. 24 (December 12, 2019): 5494. http://dx.doi.org/10.3390/s19245494.

Повний текст джерела

Анотація:

The integration of several controlled parameters within a single test system is experiencing increased demand. However, multiplexed test systems typically require complex manufacturing. Here, we describe a multiplexed immunochromatographic assay that incorporates a conventional nitrocellulose membrane, which is used together with microspot printing, to construct adjacent microfluidic “tracks” for multiplexed detection. The 1 mm distance between tracks allows for the detection of up to four different analytes. The following reagents are applied in separate zones: (a) gold nanoparticle conjugates with antibodies against each analyte, (b) other antibodies against each analyte, and (c) antispecies antibodies. The immersion of the test strip in the sample initiates the lateral flow, during which reagents of different specificities move along their tracks without track erosion or reagent mixing. An essential advantage of the proposed assay is its extreme rapidity (1–1.5 min compared with 10 min for common test strips). This assay format was applied to the detection of cardiac and inflammatory markers (myoglobin, D-dimer, and C-reactive protein) in human blood, and was characterized by high reproducibility (8%–15% coefficient of variation) with stored working ranges of conventional tests. The universal character of the proposed approach will facilitate its use for various analytes.

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Xie, Xiaofeng, Xiaodong Shao, Qiaoli Yue, Cuihao Huang, and Zhenghua Song. "Ultrasensitive Assay of Gatifloxacin at Picogram Level Based on its Enhancing Effect on the Myoglobin‐Luminol Chemiluminescence Reaction." Analytical Letters 40, no. 10 (August 2007): 1951–61. http://dx.doi.org/10.1080/00032710701385722.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Kratz, Alexander, James L. Januzzi, Kent B. Lewandrowski, and Elizabeth Lee-Lewandrowski. "Positive Predictive Value of a Point-of-Care Testing Strategy on First-Draw Specimens for the Emergency Department–Based Detection of Acute Coronary Syndromes." Archives of Pathology & Laboratory Medicine 126, no. 12 (December 1, 2002): 1487–93. http://dx.doi.org/10.5858/2002-126-1487-ppvoap.

Повний текст джерела

Анотація:

Abstract Context.—The rapid and accurate diagnosis of the etiology of chest pain is of central importance in the triage of patients presenting to emergency departments. The “first-draw” sensitivity of serum cardiac markers is known to be low on initial presentation; however, less is understood regarding the predictive value of a positive test in this situation. Objective.—To determine the ability of a critical pathway combining medical history and physical examination, electrocardiographic findings, point-of-care testing, and central laboratory data to accurately predict the presence of acute coronary ischemia. Methods.—We investigated the positive predictive value of a testing algorithm for first-draw specimens in clinical practice, combining a qualitative, point-of-care, triple-screen testing panel for cardiac markers, including myoglobin, creatine kinase–MB, and cardiac troponin I, with confirmation of the rapid assay in the central hospital laboratory by quantitative assays for creatine kinase–MB and cardiac troponin T. Results.—While a positive result on any of the individual cardiac markers of the point-of-care test had a positive predictive value for the acute coronary syndrome of only 36% (creatine kinase–MB, 41%; myoglobin, 36%; and troponin I, 65%), the positive predictive value for the diagnosis of acute coronary syndrome increased to 76% if all 3 point-of-care markers were simultaneously positive. The positive predictive value for acute coronary syndrome for a positive confirmatory result in the hospital laboratory for either creatine kinase–MB or cardiac troponin T was 61%. Among those patients with a positive marker on both the point-of-care test and the laboratory test, a careful retrospective review of the clinical history (with exclusion of patients with nonischemic cardiac pathologies and renal insufficiency) increased the positive predictive value of this algorithm to 98%. Conclusions.—Our data suggest that qualitative, point-of-care, triple-screen cardiac marker testing of patients with chest pain at initial presentation may exhibit relatively low positive predictive values. Positive predictive value can be significantly improved by rapid confirmation in the hospital laboratory and careful review of clinical findings.

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Sugasawa, Takehito, Shin-ichiro Fujita, Tomoaki Kuji, Noriyo Ishibashi, Kenshirou Tamai, Yasushi Kawakami, and Kazuhiro Takekoshi. "Dynamics of Specific cfDNA Fragments in the Plasma of Full Marathon Participants." Genes 12, no. 5 (April 30, 2021): 676. http://dx.doi.org/10.3390/genes12050676.

Повний текст джерела

Анотація:

Plasma cell-free DNA (cfDNA) is frequently analyzed using liquid biopsy to investigate cancer markers. We hypothesized that this concept might be applicable in exercise physiology. Here, we aimed to identify specific cfDNA (spcfDNA) sequences in the plasma of healthy humans using next-generation sequencing (NGS) and clearly define the dynamics regarding spcfDNA-fragment levels upon extreme exercises, such as running a full marathon. NGS analysis was performed using cfDNA of pooled plasma collected from healthy participants. We confirmed that the TaqMan-qPCR assay had high sensitivity and found that the spcfDNA sequence abundance was 16,600-fold higher than that in a normal genomic region. We then used the TaqMan-qPCR assay to investigate the dynamics of spcfDNA-fragment levels upon running a full marathon. The spcfDNA fragment levels were significantly increased post-marathon. Furthermore, spcfDNA fragment levels were strongly correlated with white blood cell and plasma myoglobin concentrations. These results suggest the spcfDNA fragments identified in this study were highly sensitive as markers of extreme physical stress. The findings of this study may provide new insights into exercise physiology and genome biology in humans.

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Mi, Xiaona, Huiling Li, and Yifeng Tu. "An Aptamer Biosensing Strategy for Label-Free Assay of Dual Acute Myocardial Infarction Biomarkers Built upon AuNPs/Ti3C2-MXenes." Chemosensors 11, no. 3 (February 24, 2023): 157. http://dx.doi.org/10.3390/chemosensors11030157.

Повний текст джерела

Анотація:

The sensitive quantification of cardiac troponin I (cTnI) and myoglobin (Myo) in blood is essential for an early emergency diagnosis of acute myocardial infarction (AMI). Attributed to AuNPs and a titanium element on the surface of the AuNPs/Ti3C2-MXenes hybrid, each respective aptamer strand can be immobilized on. In this work, a nanohybrid was deposited on amino-functionalized indium tin oxide (ITO) via an Au–N bond; thereafter, it could catch cTnI-specific, thiol-functionalized DNA aptamer through Au–S self-assembly or Myo-aptamer via adsorption and metal chelate interaction between phosphate groups and titanium for specific recognition. Both using [Fe(CN)6]3−/4− as a signaling probe, the differential pulse voltammetric (DPV) current of the cTnI-aptasensor decreased after binding with cTnI, while the other responded to Myo via the impedimetric measurement. These developed biosensors enable the response to the femtogram/mL level cTnI or nanogram/mL level Myo. Remarkably, the proposed aptasensors exhibit high sensitivity and specificity for targets and display great potential for applications in clinic diagnosis.

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Üstün, Elvan, Serpil Demir, Feyzullah Coşkun, Murat Kaloğlu, Onur Şahin, Orhan Büyükgüngör, and İsmail Özdemir. "A theoretical insight for solvent effect on myoglobin assay of W(CO)4L2 type novel complexes with DFT/TDDFT." Journal of Molecular Structure 1123 (November 2016): 433–40. http://dx.doi.org/10.1016/j.molstruc.2016.07.002.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

50

McCuskey, C. F., G. X. Brogan, S. Friedman, J. Bock, D. Cooling, L. Berrutti, and H. Thode. "Early identification of patients with acute myocardial infarction: The utility of a new rapid quantitative assay for serum myoglobin." Annals of Emergency Medicine 23, no. 3 (March 1994): 630. http://dx.doi.org/10.1016/s0196-0644(94)80373-0.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Статті в журналах з теми "Myoglobin Assay"

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями